Keprys

Keprys is a brand name for an injectable medication containing the active ingredient aminolevulinic acid hydrochloride. It is used in the treatment of actinic keratosis (AK), a common pre-cancerous skin condition. Actinic keratosis appears as rough, scaly patches on sun-exposed skin, and if left untreated, can develop into squamous cell carcinoma.

Keprys works through a process called photodynamic therapy (PDT). When applied to the skin, aminolevulinic acid is absorbed by abnormal cells, including actinic keratosis cells. These cells then convert aminolevulinic acid into a photosensitizing agent called protoporphyrin IX (PpIX). When the treated area is exposed to a specific wavelength of light (typically blue light), the PpIX is activated and produces reactive oxygen species. These reactive oxygen species selectively destroy the abnormal cells, including the actinic keratosis lesions.

The treatment involves applying the Keprys solution to the affected skin areas. After a waiting period, the lesions are exposed to the prescribed light source. Multiple treatment sessions may be required to achieve the desired outcome. Common side effects associated with Keprys treatment can include redness, stinging, burning, crusting, and temporary changes in skin color at the application site. It is important to follow the instructions of a healthcare professional carefully when using Keprys and to protect the treated skin from sunlight after the procedure.